Use of Foscarnet Therapy for EBV Infection following Control of PTLD with Enhancement of Cellular Immunity in a Lung-Transplant Recipient. (14th February 2011)

• Record Type: Journal Article
• Authors: Afshar, Kamyar; Rao, A. Purush; Patel, Vipul; Forrester, Kevin; Ganesh, Sivagini
• Other Names: Krams Sheri M. Academic Editor.
• Is Part Of: Journal of transplantation. Volume 2011(2011)
• Publication Date: 2011-02-14
• Subjects: Transplantation of organs, tissues, etc -- Periodicals; 617.95405
• DOI: 10.1155/2011/919651
• Languages: English
• ISSNs: 2090-0007

Abstract

Abstract : Posttransplant lymphoproliferative disorder (PTLD) is a serious complication following solid organ transplantation with an annual incidence rate of 3–5% in lung-transplant recipients. Pathogenesis indicates a strong association with functional over-immunosuppression and EBV infection. Clinical improvement is generally observed with reduction in immunosuppression intensity alone. We present a case of a 24-year-old woman with EBV-associated PTLD following lung transplant where decreasing the immunosuppression improved PTLD but was ineffective against controlling the EBV infection. Foscarnet in combination with immunoglobulins was successfully administered to cause a remission of the EBV infection. This is the second case reported of a persistent EBV infection after reducing immunosuppression levels and evidence of PTLD remission that required foscarnet for EBV infection control.